Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Founded in December 2019, RTK Group, LLC is a Boston-based biopharmaceutical advisory and investment fund. The firm focuses on supporting companies that develop technologies with disruptive potential in the healthcare sector. RTK Group invests across various stages, including pre-seed to IPO, and has a portfolio of four companies.
RTK Group invests in emerging technologies within the healthcare sector, specifically targeting biotechnology, pharmaceuticals, medical devices, and diagnostics. The firm supports both early and late-stage ventures, including crossover rounds and strategic financing. They embrace scientific risk to accelerate innovations that significantly improve patient lives.
Notable portfolio companies include BridgeHealth Pharmaceuticals, which develops dosage-optimized formulations; Unravel Biosciences, focused on AI-driven drug development; ROMEg Therapeutics, LLC, known for the FDA-approved drug Gloperba®️ for gout; and RxM Therapeutics, which creates palatable drug formulations for pediatric and elderly patients.
To pitch RTK Group, email your deck to info@rtkgrp.com.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.